Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Maze Therapeutics, Inc.
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 06, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 11, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 02, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 12, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
July 10, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 29, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 14, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
May 13, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
March 31, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 07, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Tickers
MAZE
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
January 30, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.